//
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review
Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?
Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research
Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease
Defining Staged Procedures for Percutaneous Coronary Intervention Trials A Guidance Document
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
Major trials in coronary intervention from 2018